Skip to main content

Advertisement

Table 1 Baseline characteristics and concomitant diseases

From: Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

Patient GA at birth AA at injection Birthweight Comcomitant diseases
1 24 5/7 OD: 37 3/7 500 g apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, kidney insufficiency, arterial hypotension, hyperbilirubinemia, anemia
OS: 32 6/7
2 24 5/7 OD 34 3/7 450 g apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, arterial hypotension, hyperbilirubinemia, anemia, hernia inguinalis, sepsis, neutropenia
3 24 4/7 OD: 34 4/7 665 g apnea and bradycardia syndrome, , RDS, neonatal infection, urinary tract infection, intracerebral hemorrhage pneumonia, arterial hypotension, hyperbilirubinemia, anemia, bronchopulmonary dysplasia, kidney insufficiency
OS: 35 5/7
4 26 1/7 OS: 38 6/7 745 g apnea and bradycardia syndrome, RDS, hyperbilirubinemia, anemia
  1. GA = gestational age; RDS = respiratory distress syndrome; AA = Adjusted age.